CELEX: 32016M8192
Language: en
Date: 2016-10-10 00:00:00
Title: Commission Decision of 10/10/2016 declaring a concentration to be compatible with the common market (Case No COMP/M.8192 - ADVENT INTERNATIONAL / THL / INVENTIV) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

|[pic]                             |EUROPEAN COMMISSION                                                                                      |

                                        Brussels, 10.10.2016
                                        C(2016) 6603 final

                                        [pic]

                                        [pic]

                                        To the notifying parties

Dear Sirs,

Subject:    Case M.8192 – ADVENT INTERNATIONAL / THL / INVENTIV   Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC)
         No 139/2004[1] and Article 57 of the Agreement on the European Economic Area[2]

 1. On 15/09/2016, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger  Regulation  by
    which Advent International (US) and Thomas H. Lee Partners (US) acquire within the meaning of  Article  3(1)(b)  of  the  Merger  Regulation
    control of part of inVentiv (US) by way of purchase of shares.[3]

 2. The business activities of the undertakings concerned are:

      – Advent International is a private equity investor. It acquires equity stakes (both controlling and non-controlling) in companies  in  the
        following sectors: business and financial services; healthcare; industrial; retail, consumer  and  leisure;  and  technology,  media  and
        telecoms.

      – THL is a private equity firm that invests in global businesses in the  following  broad  sectors:  consumer  and  healthcare;  media  and
        information services; and business and financial services.

      – inVentiv  is  a  global  provider  of  clinical  development  and  commercialisation  services.  Its  main  clients  are  pharmaceutical,
        biotechnology, generic drug and medical device companies.

 3. After examination of the notification, the European Commission has concluded that the notified operation  falls  within  the  scope  of  the
    Merger Regulation and of paragraph 5(c) of the Commission Notice on a simplified procedure for treatment  of  certain  concentrations  under
    Council Regulation (EC) No 139/2004.[4]

 4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose  the  notified  operation
    and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b)
    of the Merger Regulation and Article 57 of the EEA Agreement.

                                        For the Commission

                                        (Signed)
                                        Johannes LAITENBERGER
                                        Director-General
-----------------------
[1]   OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the  European  Union
    ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market'  by  'internal  market'.  The
    terminology of the TFEU will be used throughout this decision.
[2]   OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').
[3]   Publication in the Official Journal of the European Union No C 347, 22.9.2016, p. 37.
[4]   OJ C 366, 14.12.2013, p. 5.

-----------------------

                                                                  PUBLIC VERSION

                                                           SIMPLIFIED MERGER PROCEDURE